In the same vein, targeting DDR1 alone or in combination with other chemotherapies have been suggested in several neoplasms, including metastatic colorectal cancer, K-RAS driven lung adenocarcinoma, and breast carcinoma [14,52,53,54]. This evidence concerns the gene KRAS and breast carcinoma.